Taysha Gene Therapies (TSHA) Assets Average (2022 - 2025)
Taysha Gene Therapies (TSHA) has disclosed Assets Average for 4 consecutive years, with $329.9 million as the latest value for Q4 2025.
- Quarterly Assets Average rose 93.75% to $329.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $329.9 million through Dec 2025, up 93.75% year-over-year, with the annual reading at $251.8 million for FY2025, 51.21% up from the prior year.
- Assets Average hit $329.9 million in Q4 2025 for Taysha Gene Therapies, up from $324.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $329.9 million in Q4 2025 to a low of $91.6 million in Q2 2023.
- Historically, Assets Average has averaged $177.9 million across 4 years, with a median of $162.9 million in 2024.
- Biggest five-year swings in Assets Average: plummeted 40.6% in 2023 and later skyrocketed 93.75% in 2025.
- Year by year, Assets Average stood at $118.9 million in 2022, then soared by 55.0% to $184.2 million in 2023, then fell by 7.58% to $170.3 million in 2024, then skyrocketed by 93.75% to $329.9 million in 2025.
- Business Quant data shows Assets Average for TSHA at $329.9 million in Q4 2025, $324.9 million in Q3 2025, and $235.8 million in Q2 2025.